Artelo Biosciences Inc (ARTL) Stock Price, Quote & News

Company Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumat...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 925 7049

Website: www.artelobio.com

Address:

505 Lomas Santa Fe, Suite 160, Solana Beach, United States

Avenirlis Dec. 5 at 4:25 AM

$ARTL

0 · Reply

GoldensLairsTrading Dec. 5 at 12:08 AM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $ZM $CM $UPXI $NTSK $ARTL C

0 · Reply

VincentVanGoghh Dec. 4 at 10:52 PM

$QCLS $ARTL $CAPR $PLRZ $SMX ... watch DEVS , look what SMX did and DEVS just locked in a potential $402 M bond allocation for a flagship biomass-to-fuel facility in Louisiana that’s a massive step towards producing carbon negative SAF and green methanol at commercial scale......

0 · Reply

GoldenTradez Dec. 4 at 10:29 PM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $ARTL $MCRP $CAMT $NXPI $VRME €

0 · Reply

sweet_Journey Dec. 4 at 9:47 PM

🚀 $RUBI 🚀 $VRAX $ARTL $PMAX $KXIN

1 · Reply

Just_for_Fun Dec. 4 at 9:41 PM

$ARTL $DUO moving up neck n neck!

0 · Reply

GoldenSteers__ Dec. 4 at 9:10 PM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $FROG $ARTL $WWR $ALK Pitss

0 · Reply

ProfessorDman1 Dec. 4 at 9:01 PM

$ARTL 1.66-1.68 swing idea : nice finish 2.06 ✅

1 · Reply

DaBullRunner Dec. 4 at 8:49 PM

$ARTL watching … 🚨EPOW🚨 just received a $30M contract AH That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my $TSLA $COIN profits into EPOW👇💰💰💰 $SMX $PMI let’s get it bulls

0 · Reply

z____b1 Dec. 4 at 8:49 PM

$ARTL

0 · Reply

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 8:30 AM EST - 4 weeks ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Oct 27, 2025, 8:00 AM EDT - 5 weeks ago

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Oct 15, 2025, 9:15 AM EDT - 7 weeks ago

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Oct 1, 2025, 4:05 PM EDT - 2 months ago

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Sep 30, 2025, 8:30 AM EDT - 2 months ago

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Sep 29, 2025, 7:15 PM EDT - 2 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

Sep 29, 2025, 8:30 AM EDT - 2 months ago

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Sep 5, 2025, 4:05 PM EDT - 3 months ago

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Sep 4, 2025, 8:37 AM EDT - 3 months ago

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Sep 3, 2025, 11:33 AM EDT - 3 months ago

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Sep 3, 2025, 8:45 AM EDT - 3 months ago

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Aug 25, 2025, 7:55 AM EDT - 3 months ago

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Aug 13, 2025, 8:00 AM EDT - 4 months ago

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 9:15 AM EDT - 4 months ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Aug 4, 2025, 7:30 AM EDT - 4 months ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Aug 1, 2025, 7:45 AM EDT - 4 months ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Jul 9, 2025, 7:50 AM EDT - 5 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Jul 8, 2025, 3:06 PM EDT - 5 months ago

Artelo Biosciences Analyst See It As An Emerging Biotech

Jul 7, 2025, 7:45 AM EDT - 5 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Jun 30, 2025, 7:45 AM EDT - 5 months ago

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Jun 26, 2025, 8:00 AM EDT - 5 months ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Jun 11, 2025, 8:30 AM EDT - 6 months ago

Artelo Biosciences Announces Reverse Stock Split

Jun 5, 2025, 9:00 AM EDT - 6 months ago

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Jun 2, 2025, 9:00 AM EDT - 6 months ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

May 13, 2025, 8:00 AM EDT - 7 months ago

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 28, 2025, 8:45 AM EDT - 7 months ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Mar 31, 2025, 8:30 AM EDT - 8 months ago

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Mar 3, 2025, 8:00 AM EST - 9 months ago

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Feb 14, 2025, 9:00 AM EST - 10 months ago

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Feb 11, 2025, 9:00 AM EST - 10 months ago

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Jan 13, 2025, 9:00 AM EST - 11 months ago

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Dec 9, 2024, 9:15 AM EST - 1 year ago

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Nov 18, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Nov 13, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Nov 5, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Oct 9, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 15, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

Jul 3, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

May 29, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

May 13, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

Apr 23, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Apr 22, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Mar 12, 2024, 9:15 AM EDT - 1 year ago

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

Feb 15, 2024, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

Avenirlis Dec. 5 at 4:25 AM

$ARTL

0 · Reply

GoldensLairsTrading Dec. 5 at 12:08 AM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $ZM $CM $UPXI $NTSK $ARTL C

0 · Reply

VincentVanGoghh Dec. 4 at 10:52 PM

0 · Reply

GoldenTradez Dec. 4 at 10:29 PM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $ARTL $MCRP $CAMT $NXPI $VRME €

0 · Reply

sweet_Journey Dec. 4 at 9:47 PM

🚀 $RUBI 🚀 $VRAX $ARTL $PMAX $KXIN

1 · Reply

Just_for_Fun Dec. 4 at 9:41 PM

$ARTL $DUO moving up neck n neck!

0 · Reply

GoldenSteers__ Dec. 4 at 9:10 PM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $FROG $ARTL $WWR $ALK Pitss

0 · Reply

ProfessorDman1 Dec. 4 at 9:01 PM

$ARTL 1.66-1.68 swing idea : nice finish 2.06 ✅

1 · Reply

DaBullRunner Dec. 4 at 8:49 PM

0 · Reply

z____b1 Dec. 4 at 8:49 PM

$ARTL

0 · Reply

ParabolicUptrend Dec. 4 at 8:46 PM

What is happening to ticker SNSE now?! Looks like they are going to SQUEEZE ticker SNSE up next .. SNSE is breaking out like crazy.. Are they pumping up SNSE for 300% !? Its insane what's going on in this market.. Looks like all eyes are going to SNSE now.. Watching: $PATH $ONMD $TOVX $ARTL 2

0 · Reply

BearSqueeZZzzz Dec. 4 at 8:12 PM

$ARTL The Professor has done a nice job here. Low Floater that has broken the 1.94 Liquidity Level. The Bears 🐻 will be tossing in their sleep 💤. In fact, if I was a Bear 🐻, I would not sleep tonight 🌙.

0 · Reply

ProfessorDman1 Dec. 4 at 7:45 PM

$SMX $3 to $120 run 🏃‍♂️ 🤷‍♂️ monster parabolic … finally did it $ARTL huge discount at the moment and Buying opportunity another low floater at bottomed out .. ongoing/upcoming catalyst with positive Pre clinical We also witnessed $PLRZ run

1 · Reply

AndrevanRijsbergen Dec. 4 at 7:21 PM

$ARTL bought 1000 shares for 1,72. Company is legit, management is dedicated to succeed. Exciting studies, if they yield a cure for some ugly disease's slot of people can be helped and the company gets double rewards for there efforts.

0 · Reply

topstockalerts Dec. 4 at 6:21 PM

$ARTL setting up nicely.. 🍾

0 · Reply

ProfessorDman1 Dec. 4 at 6:19 PM

$ARTL $CAPR $PLRZ $QCLS $SMX (ARTL $5+ next ) watch this one closely

0 · Reply

ProfessorDman1 Dec. 4 at 5:59 PM

$ARTL $SMX $115 baby boom $ARTL $5-10+ next

1 · Reply

z____b1 Dec. 4 at 5:54 PM

$ARTL okay!

0 · Reply

ProfessorDman1 Dec. 4 at 5:50 PM

$SMX there she goes $100+ as I just analyzed at $60 earlier today $ARTL 1st run target 3.50-5 range second double digits play multi day

0 · Reply

ProfessorDman1 Dec. 4 at 5:19 PM

$ARTL $SMX ( ARTL next runner )

0 · Reply

ProfessorDman1 Dec. 4 at 5:12 PM

$SMX $3 to $70+ now about to break that going $100+ next $ARTL next 100%-500% swing play

1 · Reply

ProfessorDman1 Dec. 4 at 5:08 PM

$ARTL $CAPR $PLRZ $QCLS $SMX ( we are buying sub $2 > 2.50 can break tonight > into $3+ for ARTL

0 · Reply

Market Cap	3.63M
Revenue (ttm)	0.00
Net Income (ttm)	-9.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	640,500
Avg Vol	735,732
Day's Range	N/A - N/A
Shares Out	2.02M
Stochastic %K	29%
Beta	1.06
Analysts	Hold
Price Target	$18.00